Renal Impairment, C. difficile Recurrence, and the Differential Effect of Bezlotoxumab: A Post Hoc Analysis of Pooled Data From 2 Randomized Clinical Trials

BACKGROUND: Renal impairment is not a consistently cited risk factor for recurrent Clostridioides difficile infection (rCDI). We examined the association between renal impairment and rCDI and the effect of bezlotoxumab, an anti–toxin B monoclonal antibody, in reducing rCDI in participants with renal...

Descripción completa

Detalles Bibliográficos
Autores principales: Golan, Yoav, DuPont, Herbert L, Aldomiro, Fernando, Jensen, Erin H, Hanson, Mary E, Dorr, Mary Beth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7357450/
https://www.ncbi.nlm.nih.gov/pubmed/32685606
http://dx.doi.org/10.1093/ofid/ofaa248

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7357450/
https://www.ncbi.nlm.nih.gov/pubmed/32685606
http://dx.doi.org/10.1093/ofid/ofaa248

Ejemplares similares